Accessibility Menu
Instil Bio logo

Instil Bio(NASDAQ) TIL

Current Price$7.24
Market Cap$48.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-98%
1 Year-78%
1 Month-7%
Instil Bio last closing stock price
MetricPriceDate
Last closeUSD 7.132026-07-24
Instil Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.91%USD 7.422026-07-17
1 month-6.68%USD 7.642026-06-24
3 month-11.48%USD 8.062026-04-24
Year to date-35.18%USD 11.002025-12-31
1 year-77.88%USD 32.242025-07-24
3 year-37.72%USD 11.452023-07-25
5 year-98.16%USD 388.402021-07-23
Since inception-98.65%USD 528.802021-03-19

Instil Bio Financials at a Glance

Market Cap

$48.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$47.38M

EPS (TTM)

-$7.08

P/E Ratio

-1.01

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$7.24

Volume

0

Open

$7.25

Previous Close

$7.24

Daily Range

$7.24 - $7.25

52-Week Range

$5.67 - $33.83

Estimated Earnings Date

Aug 12, 2026

TIL News

Foolcom-Featured.png

Instil Bio Posts Wider Loss in Q2

Motley Fool Markets TeamAug 13, 2025
investing-screen-analysis-investor-growth-stocks-getty

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

Cory RenauerSep 14, 2024
GettyImages-667015964

At a Recent Cancer Research Conference, Instil Bio Stole the Show

Patrick BafumaApr 29, 2021

TIL: Motley Fool Moneyball Superscore

12

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Instil Bio

Instil Bio develops new treatments for people with cancer. Its therapies aim to help patients whose cancers have not responded to standard care. The company focuses on using the body’s own immune system to fight tumors.

What’s in the Instil Bio Toolbox?

  • Bispecific Antibodies: Proteins designed to target two cancer-related molecules at once; for patients with solid tumors. (0% of revenue; no product sales)
  • Monoclonal Antibodies: Lab-made proteins that attach to specific cancer cell markers; for advanced cancer cases. (0% of revenue)
  • Cell Therapy Pipeline: Uses a patient’s own immune cells to attack tumors; focused on melanoma and other solid cancers. (0% of revenue)
  • Facility Rental: Leases a manufacturing site to AstraZeneca, generating rental income. (Majority of reported income; not product revenue)

Growth Moves: Instil Bio’s Expansion Playbook

  • In 2024, in-licensed bispecific and monoclonal antibody programs from ImmuneOnco.
  • Shifted focus from cell therapy to antibody-based drugs in 2024.
  • Leased Tarzana facility to AstraZeneca in 2024, creating a new income stream.
  • Closed UK operations and reduced workforce in 2024 to cut costs.
  • Raised $6.6 million through an equity offering in Q2 2025.

Why Instil Bio Stands Out (Without the Lab Coat)

Instil Bio holds exclusive rights to new antibody drugs outside China, giving it access to unique technology. The company relies on partnerships for clinical data and manufacturing, reducing its own infrastructure needs. Its business model now combines drug development with income from leasing assets.

Five Things You Need to Know

  • No product revenue reported for Q2 2025, Q2 2024, or Q2 2023.
  • Net loss was $21 million in Q2 2025, 43.4% higher loss than Q2 2024.
  • Operating expenses were $13 million in Q2 2025, a 5.3% improvement from Q2 2024.
  • Cash flow from operations improved to -$8 million in Q2 2025, up 20.6% from Q2 2024.
  • Cash, investments, and equivalents totaled $103.6 million as of June 30, 2025.

Bottom Line

Instil Bio has shifted from cell therapy to antibody drugs and asset leasing. The company’s future depends on new drug development and careful cost management.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

17

CEO

Bronson Crouch

Website

www.instilbio.com

Headquarters

Dallas, TX 75219, US

TIL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-39.76%

Return on Capital

-26.58%

Return on Assets

-23.64%

Earnings Yield

-99.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$48.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.78M

Volume

0

Avg. Volume

21.50K

Financials (TTM)

Gross Profit

-$24.00K

Operating Income

-$54.04M

EBITDA

-$41.59M

Operating Cash Flow

-$33.76M

Capital Expenditure

$0.00

Free Cash Flow

-$33.76M

Cash & ST Invst.

$74.57M

Total Debt

$85.19M

Instil Bio Performance Analysis

Instil Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Instil Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Instil Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -34.4641.8%
20232023-12-31USD -24.00-30.4%
20242024-12-31USD -11.39-52.5%
20252025-12-31USD -10.70-6.0%
Instil Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.0%
Q32025-09-3038.0%
Q42025-12-3139.8%
Q12026-03-3148.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$12.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$48.36MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.84M

N/A

Employees

17

N/A

Net Income

-$4.20M

+85.1%

EBITDA

-$2.64M

+90.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$74.57M

-28.1%

Total Debt

$85.19M

-1.7%

Accounts Receivable

$28.00K

-97.0%

Inventory

$0.00

N/A

Long Term Debt

$85.00M

+0.9%

Short Term Debt

$186.00K

-92.2%

Return on Assets

-23.64%

N/A

Return on Invested Capital

-27.61%

N/A

Free Cash Flow

-$1.34M

+68.1%

Operating Cash Flow

-$1.34M

+68.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PLRXPliant Therapeutics, Inc.
$1.09+0.93%
ATOSAtossa Therapeutics, Inc.
$2.30-4.77%
TVGNTevogen Bio Holdings Inc.
$4.49+1.81%
ONCYOncolytics Biotech Inc.
$0.81-4.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About TIL

What is the current price of Instil Bio?

Instil Bio is trading at $7.24 per share.

What is the 52-week range for Instil Bio?

Over the past 52 weeks, Instil Bio has traded between $5.67 and $33.83.

How much debt does Instil Bio have?

As of the most recent reporting period, Instil Bio reported total debt of $85.19M.

How much cash does Instil Bio have on hand?

Instil Bio reported $5.15M in cash and cash equivalents in its most recent financial results.

What is Instil Bio’s dividend yield?

Instil Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services